Shapely Review: How Its GLP-1 Care Moves From Video Visits to Pharmacy Delivery

01Start with the care team, not the medication advertisement

Shapely’s terms identify the business as Zaghi Medical, Inc., doing business as Shapely. Its advertised entry process asks about insurance and health goals, followed by a video consultation with an assigned clinician who personalizes the care plan. That is a more specific service description than a medication storefront alone. However, the consulted pages do not establish a first-appointment deadline, a complete intake questionnaire or detailed provider-specific clinical eligibility criteria beyond the advertised adult age and geographic restrictions.

The terms introduce uncertainty about who employs or oversees the treating professionals. One passage describes providers employed or contracted by Shapely; another says Shapely does not employ, supervise or control the providers delivering care and disclaims responsibility for the quality or appropriateness of their care. These statements should not be silently reconciled. Before enrolling, ask for the treating clinician’s name, professional credential, practice entity and the appropriate contact for clinical concerns.

Geographic availability is also narrower than the site’s expansion language might suggest. The documented current states are California, Florida, New York and Texas, for people 18 and older. A promise of eventual nationwide expansion does not establish access elsewhere. Our guide to clinicians and telehealth platforms explains why the platform name, treating professional and dispensing pharmacy should be understood as distinct participants rather than one interchangeable organization.

02The consultation and laboratory pathway

Shapely promises an evaluation, not a guaranteed prescription. Its terms expressly reserve prescribing to professional judgment and exclude DEA-controlled or scheduled medications and certain other drugs with abuse potential. The homepage also says clinicians can consider alternatives when GLP-1 treatment is not appropriate, including other medications, lifestyle changes, continuous glucose monitoring and other tools. These are documented possible pathways, not promises that any particular patient will receive a specific medication, device or treatment plan.

Laboratory requirements need clarification before the visit. The homepage strongly recommends recent results but says they are not required before most weight-loss medicines. It offers to order testing or accept results from the six months before enrollment. The Medicare page instead accepts results from the preceding 12 months. Neither statement should be treated as the universal rule for every patient. Ask which existing results the clinician will accept and whether additional testing would delay the prescribing decision.

For uninsured patients, Shapely advertises a flat $75 laboratory charge with an in-person blood draw at Labcorp. Membership itself does not include labs. That creates a physical step in an otherwise remote service and a potentially separate bill. Preparing records, medication lists and coverage questions before the appointment can reduce avoidable back-and-forth; our first-consultation preparation guide provides a framework without substituting for the clinician’s assessment.

03Branded prescriptions and insurance involve separate decisions

Shapely’s catalog labels Oral Wegovy, Ozempic and Wegovy as semaglutide products, and Zepbound and Mounjaro as tirzepatide products. It also lists Foundayo as orforglipron and Contrave as bupropion and naltrexone. These are descriptions of the provider’s catalog, not independent verification of each product’s regulatory status or availability. An “insurance accepted” label does not establish that a particular plan covers that medicine for a particular patient.

The company says it is in network with Medicare and most PPO plans, naming Aetna, Blue Shield and United. Those network assertions were not independently verified. Its UnitedHealthcare page acknowledges that drug coverage varies by plan and may require prior authorization or proof of medical necessity; Shapely offers help completing authorization requests. Assistance is useful, but the pages do not establish approval deadlines or guarantee that a request will succeed. Consultation coverage and medication coverage remain separate questions.

For commercial insurance, Shapely describes medication copays as typically $25 monthly while warning they may be higher. It also offers help accessing eligible-patient self-pay programs for Wegovy through NovoCare and Zepbound through Lilly Direct, while expressly disclaiming affiliation with Novo Nordisk, Eli Lilly or their patient programs. These routes should be confirmed individually, including the exact product presentation and dispensing channel. A manufacturer-program reference is not a universal price or assurance that every prescription qualifies.

04Compounded prescriptions require a clearer pharmacy handoff

Shapely separately advertises injectable compounded semaglutide and tirzepatide. It describes compounded medicines as custom-prepared prescriptions based on individual clinical evaluation, potentially involving formulations or strengths not commercially available. The company says it works exclusively with what it describes as state-licensed 503A and 503B compounding pharmacies. The consulted text does not name those pharmacies or provide their licenses, so the statement remains a provider claim rather than an independently verified pharmacy assessment.

Shapely acknowledges that compounded preparations are not FDA approved. FDA explains that these preparations do not undergo its premarket review for safety, effectiveness and quality, and recommends their use when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not establish clinical inequivalence. Equally, Shapely’s description of pharmacy standards does not make its compounded products FDA approved or establish results equivalent to branded products.

The terms say patients may direct a prescription to a pharmacy of their choice. They do not explain how that option interacts with compounded-package pricing, available formulations or shipping arrangements. Before paying, request the pharmacy name, exact prescribed product, route, included supplies and a direct pharmacy contact. Our pharmacy-handoff guide helps organize these questions. Shapely also says compounded medicines are self-pay only and are not reimbursed by insurance.

05Medication prices sit on top of membership

The prominent starting prices are not universal monthly treatment prices. Compounded injectable semaglutide starts at an advertised $99 per month within specified three-month packages; compounded injectable tirzepatide starts at $166 per month within its starter package. Both require separate membership. The table preserves the provider’s medication categories rather than translating them into patient dosing instructions. A package’s stated duration does not, by itself, establish its dispensed quantity, payment timing or minimum service commitment.

The semaglutide page says shipping, syringes and alcohol pads are included. The package advertising also mentions Affirm and Klarna and claims savings of up to 33%, but the consulted documentation does not establish financing eligibility, interest, other financing terms or when package totals are collected. Readers should obtain those details rather than assume a monthly equivalent means monthly collection—or that the displayed total necessarily means mandatory prepayment.

For care membership, the self-pay offer is $49 for the first month and $99 monthly afterward. Medications and labs are excluded. Insurance billing has additional layers: the homepage advertises a $9 first-month membership promotion, while the UnitedHealthcare page lists $49 monthly plus applicable copays and deductibles. The ongoing rate after the $9 offer is not consistently established. Request a written breakdown separating membership, clinical cost-sharing, medication and laboratory charges.

06Medicare details need confirmation before the pathway is clear

The Medicare page advertises care under a “co-pays only” heading, starting as low as $15 per month or free with secondary insurance. That is a care-price claim, not an included medication price. Elsewhere, Shapely describes continuing membership charges for app access, team chat, education, tracking tools and medication-location assistance, along with possible insurance cost-sharing. The documentation does not clearly establish how every Medicare arrangement fits those broader membership descriptions.

There is also a material difference in drug-coverage explanations. The homepage limits its Medicare description to patients with diabetes, cardiovascular disease or obstructive sleep apnea. The Medicare page instead says eligible Part D patients can access Wegovy, Zepbound and Foundayo for $50 monthly through a Medicare GLP-1 Bridge program beginning July 1, 2026. This is Shapely’s assertion; the program and its eligibility conditions were not independently verified in this review.

These statements should not be combined into a promise of universal Medicare access. Ask Shapely and the plan to confirm the relevant coverage route, required eligibility documentation, exact medicine, pharmacy channel and all separate care charges. Also clarify which laboratory-result window applies, since the Medicare page allows 12 months rather than the homepage’s six. Written answers would make the financial and clinical sequence easier to understand before booking or purchasing medication.

07Two-day shipping leaves several clocks unaccounted for

Both injection pages advertise free two-day shipping and monthly clinician video visits. The shipping statement does not define how long it takes to obtain an appointment, complete clinical review, resolve an authorization, prepare a prescription or dispatch the medicine. It also does not establish that arrival occurs two days after enrollment. Those are separate steps, potentially handled by different organizations, and the consulted documentation does not give a guaranteed end-to-end timetable.

Other delivery responsibilities remain unclear. The pages do not specify refrigerated transport arrangements, package tracking, delivery restrictions or procedures for losses, delays and damage. Before ordering an injectable, ask who sends tracking information, which organization handles a failed delivery and how to reach the dispensing pharmacy. Free shipping describes a charge inclusion; it does not mean treatment is free or demonstrate that replacement medication will be provided without an additional charge.

FDA explicitly advises not using an injectable GLP-1 medicine that arrives warm or inadequately refrigerated and contacting the provider or dispensing pharmacy to resolve the concern. That guidance is not evidence that Shapely has a shipping problem; it identifies a responsibility the public pages leave underexplained. Our guide to warm injectable deliveries provides context for asking about handling concerns without attempting to judge a product’s usability from a review.

08Follow-up is a documented strength, but response standards are missing

Shapely’s advertised ongoing service is comparatively specific: monthly video visits, one-to-one access to a personalized dietitian, unlimited chat and app support, help obtaining coverage and assistance finding medication at local pharmacies. It also advertises a cellular-enabled scale for use during participation, with an explicit exclusion when Aetna or Cigna is the primary insurer. These features describe a continuing care structure, rather than simply a recurring medication purchase, although the consulted pages do not establish support-response deadlines.

NIDDK describes follow-up as attention to treatment response and tolerability, with medication accompanying healthy eating and physical activity. Shapely’s monthly visits and dietitian offering create opportunities for that work, but the public documentation does not show a detailed monitoring protocol or measured clinic outcomes. Its testimonials are disclosed as shared with permission and compensated for usage rights, with results varying. They should not be treated as clinical evidence of likely results for a new patient.

Communication and exit arrangements also warrant preparation. The terms warn that texts and emails may not be encrypted and could be intercepted. Ask which channel is appropriate for sensitive information and urgent clinical questions. The consulted documentation does not establish cancellation deadlines, automatic-renewal mechanics, refunds, medication returns or early departure from three-month packages; part of the available terms text was omitted. Stopping future payments, obtaining a refund and arranging continued clinical care are separate matters.

Questions & answers

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

1. FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
2. NIDDK: prescription medications for overweight and obesity ↗
3. Shapely — weightloss/insurance/unitedhealthcare ↗
4. Shapely — weightloss/medications/semaglutide ↗
5. Shapely — terms of use ↗
6. Shapely — official website ↗
7. Shapely — weightloss/insurance/medicare ↗
8. Shapely — weightloss/medications/tirzepatide ↗

Continue reading

• The GLP-1 Care Journey: Who Handles Intake, Prescribing, Delivery and Follow-Up?
• From Prescription to Dispensing: Questions for the GLP-1 Pharmacy Handoff
• GLP-1 Approval, Dispatch and Arrival Are Different Clocks
• What Ongoing GLP-1 Support Actually Means
• How Insurance and Self-Pay Change the GLP-1 Care Pathway